Skip to main content
HLNHaleon plcSell5.0·$9.70-1.02%
SellModerate Confidence
Investment thesis

Haleon offers a financially sound consumer health franchise with strong margins and a favorable risk/reward setup, but a death cross and sustained negative price momentum block near-term entry; the thesis requires a technical reversal before the asymmetric upside becomes actionable.

Thesis pillars

  • Quality Margins PiotroskiStable
  • Death Cross Price MomentumDeteriorating
  • Asymmetric Upside Risk RewardImproving
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Haleon plc (HLN) Stock Analysis

SellModerate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Sell if holding. Momentum 3.1/10 is below the 5.0 floor at $9.70 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Thin upside margin: 7.6%; Weak growth.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such... Read more

QualityF-score7 / 9FCF yield4.17%
IncomeYield2.02%Payout39.53%sustainable
Stop $9.28Target $10.43(analyst − 13%)A.R:R 1.5:1
Analyst target$11.99+23.6%5 analysts
$10.43our TP
$9.70price
$11.99mean
$14

Sell if holding. Momentum 3.1/10 is below the 5.0 floor at $9.70 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Thin upside margin: 7.6%; Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 193d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-08-15
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Feb 24, 2027193d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Thin upside margin: 7.6%
Weak growth
Negative momentum

Key Metrics

P/E (TTM)20.0
P/E (Fwd)15.7
Mkt Cap$43.2B
EV/EBITDA17.9
Profit Mgn14.6%
ROE10.1%
Rev Growth2.2%
Beta0.24
Dividend2.02%
Rating analysts26

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C1.17bearish
IV70%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
1.1
Revenue Growth
3.0

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.0
Obv
1.0
Macd
3.0
Rsi
5.5
Ma Position
6.0
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 3.1<4.5A.R:R 1.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 193d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
43 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $9.56Resistance $10.25

Price Targets

$9
$10
A.Upside+7.6%
A.R:R1.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! momentum at 3.1 (below the engine's 4.5 threshold)

Earnings

B
M
M
M
1/4 beats
Next Earnings2027-02-24 (193d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is HLN stock a buy right now?

Sell if holding. Momentum 3.1/10 is below the 5.0 floor at $9.70 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Thin upside margin: 7.6%; Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $9.28. Score 5.0/10, moderate confidence.

What is the HLN stock price target?

Take-profit target: $10.43 (+7.6% upside). Prior stop was $9.28. Stop-loss: $9.28.

What are the risks of investing in HLN?

Thin upside margin: 7.6%; Weak growth; Negative momentum.

Is HLN overvalued or undervalued?

Haleon plc trades at a P/E of 20.0 (forward 15.7). TrendMatrix value score: 5.6/10. Verdict: Sell.

What do analysts say about HLN?

26 analysts cover HLN with a consensus score of 4.0/5. Average price target: $12.

What does Haleon plc do?Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various...

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Related stocks: NBIX (Neurocrine Biosciences, Inc.) · KNSA (Kiniksa Pharmaceuticals Interna) · LNTH (Lantheus Holdings, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · AMRX (Amneal Pharmaceuticals, Inc.)
Home Stocks HLN

Latest news

Latest News

TradingKey17d ago
Kalkine Media24d ago
Bez Kabli45d ago
Marketscreener.com45d agoProduct
Morningstar16d ago
Seeking Alpha16d agoEarnings
Marketscreener.com16d ago
TradingView16d agoEarnings
Proactive financial news16d ago
Marketscreener.com16d ago
Smartkarma16d agoEarnings
TipRanks16d ago
TradingView16d ago
Tradingview.com16d agoEarnings
Yahoo Finance51d ago
Bez Kabli51d ago
MarketBeat51d ago
Dars.gov.et23d ago
Yahoo Finance44d agoProduct
TradingView44d ago
Loading more...